- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Pelthos Therapeutics Inc (PTHS)
Track today's live Pelthos Therapeutics (PTHS) share price, performance and key data on this page with our current NYSE:PTHS stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Pelthos Therapeutics share price on the NYSE exchange. Use the dropdown to switch exchange for the PTHS share price, head to our technical summary section, which provides analysis on Pelthos Therapeutics share price buy/sell indicators using real-time data (or discuss the Pelthos Therapeutics (PTHS) stock price today with other investors in the Pelthos Therapeutics NYSE share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NYSE:PTHS share price (ISIN: US1711262048) to enhance your trading decisions with our free investment tools and resources.
What Is the Pelthos Therapeutics Inc Share Price Today?
The Pelthos Therapeutics share price today is 7.440.
What Is the Stock Symbol for Pelthos Therapeutics Inc
The stock symbol (or 'ticker') for Pelthos Therapeutics Inc is "PTHS."
What Stock Exchange Does Pelthos Therapeutics Inc Trade On?
Pelthos Therapeutics Inc is listed and trades on the NYSE stock exchange.
Is Pelthos Therapeutics Inc a Good Stock to Buy?
Determining whether Pelthos Therapeutics (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NYSE:PTHS share price (ISIN: US1711262048) to enhance your trading decisions with our free investment tools and resources.
What Is the Pelthos Therapeutics Inc Share Price Today?
The Pelthos Therapeutics share price today is 7.440.
What Is the Stock Symbol for Pelthos Therapeutics Inc
The stock symbol (or 'ticker') for Pelthos Therapeutics Inc is "PTHS."
What Stock Exchange Does Pelthos Therapeutics Inc Trade On?
Pelthos Therapeutics Inc is listed and trades on the NYSE stock exchange.
Is Pelthos Therapeutics Inc a Good Stock to Buy?
Determining whether Pelthos Therapeutics (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.270
8.460
52 wk Range
7.270
34.680
Trading near 52-week Low
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.2708.460
52 wk Range
7.27034.680
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PTHS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
49.571
Upside
+566.28%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Form 8K Pelthos Therapeutics Inc For: 12 November- Investing.com
Form 13D/A Pelthos Therapeutics Inc. For: 3 November- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 49.571
(+566.28% Upside)
Pelthos Therapeutics Inc Earnings Call Summary for Q3/2026
- Pelthos reported Q3 2026 EPS of -$2.04, missing estimates of -$0.29 by 603%, though revenue rose to $15.39M on strong Zelsuvmi sales growth of 114% YoY.
- Net loss narrowed to $7.9M from $23.4M in Q2; COGS fell 53% sequentially while SG&A expenses dropped 25% to $18.8M, showing improved operating efficiency.
- Company ended quarter with $17.7M cash and gross-to-net ratio of 31.5%; new PBM agreement covers 24M lives, removing prior authorization barriers for Zelsuvmi.
- Management expects seasonal strength in H1 2027 with gross-to-net moving to mid-30% range; Xepi launch targeted for March 2027, XEGLYZE by end of Q3 2027.
- Castle Creek acquisition announced to add D-Fi gene therapy for rare disease, expected to close Q1 2027; stock trades at $9.27, near 52-week low of $8.72.
Last Updated: 12/11/2026, 14:44
Read Full TranscriptEarnings
Latest Release
12/11/2026
EPS / Forecast
-2.04 / -0.29
Revenue / Forecast
15.39M / --
Compare PTHS to Peers and Sector
Metrics to compare | PTHS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPTHSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.3x | −1.6x | −0.2x | |
PEG Ratio | 0.00 | −0.03 | 0.00 | |
Price/Book | −19.0x | 1.3x | 2.6x | |
Price / LTM Sales | 0.7x | 36.1x | 2.8x | |
Upside (Analyst Target) | - | 599.3% | 65.0% | |
Fair Value Upside | Unlock | 23.0% | 9.6% | Unlock |
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Pelthos Therapeutics (NYSE: PTHS) Share Price Today?
The Pelthos Therapeutics stock price today is 7.440 USD.
What Stock Exchange Does Pelthos Therapeutics (PTHS) Trade On?
Pelthos Therapeutics is listed and trades on the New York Stock Exchange.
What Is the Ticker (Stock Symbol) for Pelthos Therapeutics?
The stock symbol (also called a 'ticker') for Pelthos Therapeutics is "PTHS."
What Is the Current Pelthos Therapeutics Market Capitalisation?
As of today, Pelthos Therapeutics (NYSE: PTHS) market cap is 30.740M USD.
What Is Pelthos Therapeutics's (PTHS) Earnings Per Share (TTM)?
The Pelthos Therapeutics EPS is currently -26.36 (Trailing Twelve Months).
Is PTHS a Buy or Sell From a Technical Analyst Perspective?
Based on today's Pelthos Therapeutics moving averages and other technical indicators, the daily buy/sell signal for PTHS stock is Strong Sell.
How Many Times Has Pelthos Therapeutics Stock Split?
Pelthos Therapeutics has split 1 times. (See the PTHS stock split history page for full effective split date and price information.)
How Many Employees Does Pelthos Therapeutics Have?
Pelthos Therapeutics has 92 employees, based on their latest Companies House report.
What is the current trading status of Pelthos Therapeutics (NYSE: PTHS)?
As of 14/11/2026, Pelthos Therapeutics (PTHS) is trading at a share price of 7.440 USD, with a previous close of 7.440 USD. The stock has fluctuated within a day range of 7.270 USD to 8.460 USD, while its 52-week range spans from 7.270 USD to 34.680 USD.
What Is Pelthos Therapeutics (PTHS) Price Target According to Analysts?
The average 12-month price target for Pelthos Therapeutics is 49.571 USD, with a high estimate of 64 USD and a low estimate of 30 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +566.28% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.